Gannet and Re-Vana Partner to Scale Ocular Drug Polymers
The agreement secures cGMP manufacturing for polymer platforms that support upcoming clinical-stage eye treatment programs.
Updated on Oct. 27, 2026 in Biotech
Live Poll
Do you trust that pharmaceutical company partnerships prioritize faster access to new medical treatments for patients?
Gannet BioChem and Re-Vana Therapeutics have signed an agreement to develop and manufacture biodegradable polymer platforms for drug delivery. The announced partnership aims to scale materials for Re-Vana's EyeLief and OcuLief programs as the company progresses toward clinical development.
Why it matters
This partnership seeks to standardize and scale the production of specialized polymers necessary for sustained-release ocular therapies. By combining macromer chemistry with manufacturing expertise, the companies are aiming to stabilize material quality for upcoming clinical trials.
The collaboration integrates Re-Vana's proprietary macromer chemistry—large molecules composed of repeating subunits—with Gannet's established poly(ethylene glycol) (PEG) chemistry and manufacturing processes. These polymers are intended to serve as the structural foundation for sustained-release drug delivery systems.
The players
Gannet BioChem
A Huntsville-based chemical manufacturer specializing in PEG chemistry with 30 years of industry experience.
Re-Vana Therapeutics
A Belfast-founded biotechnology company focused on sustained-release drug delivery platforms for ocular diseases.
The details
The agreement focuses on developing and scaling manufacturing processes for biodegradable polymers that act as controlled-release vehicles for ocular drugs. Gannet BioChem will utilize its facilities to perform analytical characterization and cGMP (current Good Manufacturing Practice) manufacturing, which ensures that products are consistently produced and controlled according to quality standards. This process aims to eliminate variability in material consistency and support the regulatory requirements needed for Re-Vana to enter clinical trials.
Timeline
October 27, 2026: The partnership agreement was officially announced.
October 29-30, 2026: The companies are scheduled to attend the PODD Conference in Boston.
The Tech Race
The agreement aligns with the broader push to stabilize manufacturing of complex ocular delivery systems that face high barriers to clinical-grade scaling. It positions the partners to meet the reproducibility demands required for competitive progression in the sustained-release drug market.
This development primarily affects the clinical development pipeline for Re-Vana's EyeLief and OcuLief platforms rather than immediate consumer availability. Regulatory and clinical success in upcoming trials will be the primary determinant of when these therapies reach patients.
The takeaway
The move ensures that material quality is locked into a cGMP framework early, potentially smoothing the path for upcoming clinical evaluations. Observers should track announcements regarding Re-Vana's clinical trial filings to see how these standardized polymers perform in human studies.
Further reading
For more updates on emerging platforms in the medical sector, explore our latest coverage in Biotech.
Source note: This article includes information reported by Financial Post.
Live Poll
Do you trust that pharmaceutical company partnerships prioritize faster access to new medical treatments for patients?
